Al-Marsad newspaper: The US Food and Drug Administration (FDA) has approved the marketing of the world’s most expensive drug for the treatment of the genetic disease: hemophilia B.
The agency has greenlit Hemgenix from biopharmaceutical company CSL Behring, which set its price at $3.5 million per dose, making it the most expensive treatment in the world.
Hemgenix is given intravenously, once, to adult patients with haemophilia B, an inherited blood disorder that affects mostly men and is caused by a genetic mutation in a protein essential for blood clotting. Left untreated, the condition can cause bleeding that enters organs and joints, including the brain, according to The Guardian.
One study found that it cut the number of expected bleeding episodes by more than half over the course of a year and freed 94 percent of patients from the need for regular injections to keep things under control.
